ABERDEEN, Scotland and Singapore, 26 November, 2019 – In a paper published in today’s online issue of the Journal of Alzheimer’s Disease, TauRx has reported unexpected results of a pharmacokinetic analysis of the relationship between treatment dose, blood levels and pharmacological activity of the drug hydromethylthionine on the brain in over 1,000 patients with mild-to-moderate Alzheimer’s disease. These results showed that, even at the lowest dose of hydromethylthionine previously tested in two Phase 3 global clinical trials (8 mg/day), the drug produced concentration-dependent effects on cognitive decline and brain atrophy.
Read more here.
In a paper published in today’s online issue of the Journal of Alzheimer’s Disease, TauRx has reported unexpected results of a pharmacokinetic.
